The Innovator IBD 50 ETF (FFTY) seeks to track the IBD 50 Index, which measures the performance of the top 50 growth stocks identified by Investor's Business Daily's proprietary screening methodology. This growth-focused equity ETF targets companies with strong earnings growth, sales acceleration, and technical momentum characteristics.
How It Works
FFTY uses a passively managed, equal-weighted approach that holds the 50 stocks selected by IBD's computer-driven screening process. The index identifies companies with superior earnings per share growth, return on equity, sales growth acceleration, and price performance momentum. Holdings are rebalanced quarterly to maintain equal weighting and incorporate new stock selections. The fund typically holds exactly 50 positions across various sectors, with each stock representing approximately 2% of assets.
Key Features
- Targets high-growth companies using IBD's proven screening methodology that combines fundamental and technical analysis factors
- Equal-weighted structure prevents large-cap dominance and provides balanced exposure to all 50 selected growth stocks
- Quarterly rebalancing captures momentum shifts and ensures portfolio stays aligned with IBD's latest growth stock selections
Risks
- This ETF can lose significant value during growth stock selloffs, as momentum-driven stocks often decline 40-60% in bear markets
- Equal weighting creates higher turnover costs and potential tax inefficiency compared to market-cap weighted growth ETFs
- Concentration in just 50 stocks increases single-stock risk compared to broader market ETFs with thousands of holdings
Who Should Own This
Best suited for aggressive growth investors with 3-5 year time horizons and high risk tolerance seeking concentrated exposure to momentum stocks. Works as a satellite holding (5-15% of equity allocation) for investors wanting to overweight high-growth companies beyond broad market exposure.